StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
This year
2
Publishing Date
2024 - 02 - 02
1
2024 - 01 - 10
1
2023 - 10 - 10
1
2023 - 10 - 09
1
2023 - 09 - 06
1
2023 - 08 - 27
1
2023 - 07 - 17
1
2023 - 03 - 06
1
2022 - 07 - 26
2
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 06 - 22
1
2022 - 05 - 26
1
2022 - 05 - 20
1
2022 - 03 - 14
1
Sector
Health technology
16
Tags
Aav9
1
Achondroplasia
4
Bbp-671
1
Bbp-711
1
Bbp-812
1
Biotech-bay
2
Cardiology
1
Children
2
Chmp
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
2
Disease
1
Ema
1
Fda
1
Kidney
1
Muscular dystrophy
1
N/a
11
Nulibry
1
Ongoing
1
Pharma
13
Phase 1
2
Phase 2
3
Pos
1
Positive
16
Potential
2
Ptr-01
1
Publication
2
Results
8
Study
4
Therapeutics
1
Therapy
2
Treatment
2
Trial
6
Velocity
1
Entities
Abbvie inc.
32
Adial pharmaceuticals, inc
10
Alnylam pharmaceuticals, inc.
19
Amgen inc.
17
Annovis bio, inc.
10
Aquestive therapeutics, inc.
18
Arrival
33
Astellas pharma inc
16
Astrazeneca plc
18
Beigene, ltd.
21
Beyondspring, inc.
11
Biogen inc.
13
Biontech se
18
Bridgebio pharma, inc.
16
Bristol-myers squibb company
33
Celldex therapeutics, inc.
10
Clearside biomedical, inc.
15
Coherus biosciences, inc.
24
Dare bioscience, inc.
13
Eli lilly and company
34
Fortress biotech, inc.
10
Gartner, inc.
31
Gilead sciences, inc.
14
Glaxosmithkline plc
13
Hoth therapeutics, inc.
14
I-mab
10
Immix biopharma, inc.
11
Immutep limited
12
In8bio inc
10
Incyte corporation
17
Ionis pharmaceuticals, inc.
21
Johnson & johnson
55
Kering
13
Lithium corp
18
Mediwound ltd.
11
Merck & company, inc.
21
Morgan stanley
12
Myovant sciences ltd.
10
Nasdaq, inc.
86
Novartis ag
24
Orange
40
Parsons corporation
14
Pds biotechnology corporation
12
Pfizer, inc.
46
Pliant therapeutics, inc.
10
Regeneron pharmaceuticals, inc.
26
Regenxbio inc.
17
Rocket pharmaceuticals, inc.
11
Sanofi
114
Scynexis, inc.
11
Seagen inc.
13
Sellas life sciences group, inc.
11
Sorrento therapeutics, inc.
22
Takeda pharmaceutical company limited
15
Taylor devices, inc.
17
Teva pharmaceutical industries ltd
14
Tonix pharmaceuticals holding corp.
12
Vertex pharmaceuticals incorporated
11
Viracta therapeutics inc
14
Zai lab limited
11
Symbols
BBIO
16
Exchanges
Nasdaq
16
Crawled Date
2024 - 02 - 02
1
2024 - 01 - 10
1
2023 - 10 - 10
1
2023 - 10 - 09
1
2023 - 09 - 06
1
2023 - 08 - 27
1
2023 - 07 - 17
1
2023 - 03 - 06
1
2022 - 07 - 26
2
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 06 - 22
1
2022 - 05 - 26
1
2022 - 05 - 20
1
2022 - 03 - 14
1
Crawled Time
11:00
1
12:00
9
12:20
1
12:30
1
13:00
1
18:00
1
20:00
1
22:00
1
Source
bridgebio.com
3
www.biospace.com
5
www.globenewswire.com
7
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
entities :
Bridgebio pharma, inc.
save search
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Published:
2024-02-02
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
-24.74%
|
O:
-1.41%
H:
5.51%
C:
3.26%
pharma
positive
trial
results
study
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
Published:
2024-01-10
(Crawled : 22:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
-37.17%
|
O:
-1.4%
H:
0.08%
C:
-0.31%
pharma
positive
publication
results
study
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Published:
2023-10-10
(Crawled : 12:00)
- bridgebio.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
-2.11%
|
O:
-0.04%
H:
5.51%
C:
3.67%
pharma
positive
publication
results
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Published:
2023-10-09
(Crawled : 12:00)
- bridgebio.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
-0.75%
|
O:
0.0%
H:
1.5%
C:
1.39%
pharma
positive
ongoing
potential
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
Published:
2023-09-06
(Crawled : 12:00)
- bridgebio.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
-15.36%
|
O:
0.57%
H:
2.22%
C:
-1.01%
fda
pharma
children
achondroplasia
positive
ema
trial
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
Published:
2023-08-27
(Crawled : 12:20)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
Email alert
Add to watchlist
positive
cardiology
results
study
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Published:
2023-07-17
(Crawled : 11:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
37.6%
|
O:
46.87%
H:
28.1%
C:
19.73%
positive
results
study
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published:
2023-03-06
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
130.63%
|
O:
65.5%
H:
7.78%
C:
-8.17%
velocity
positive
results
achondroplasia
phase 2
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
Published:
2022-07-26
(Crawled : 20:00)
- biospace.com/
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
127.29%
|
O:
8.43%
H:
0.0%
C:
-22.32%
pharma
children
trial
positive
results
achondroplasia
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia
Published:
2022-07-26
(Crawled : 13:00)
- biospace.com/
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
127.29%
|
O:
8.43%
H:
0.0%
C:
-22.32%
pharma
trial
positive
results
phase 2
achondroplasia
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published:
2022-07-25
(Crawled : 12:00)
- prnewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
147.0%
|
O:
0.59%
H:
8.42%
C:
8.03%
nulibry
treatment
pharma
chmp
therapeutics
positive
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
Published:
2022-06-27
(Crawled : 12:00)
- biospace.com/
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
172.5%
|
O:
0.22%
H:
2.22%
C:
1.3%
bbp-711
pharma
kidney
trial
positive
phase 1
potential
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Published:
2022-06-22
(Crawled : 12:00)
- biospace.com/
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
218.96%
|
O:
-1.02%
H:
12.96%
C:
8.61%
bbp-812
pharma
disease
aav9
positive
therapy
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
Published:
2022-05-26
(Crawled : 18:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
278.13%
|
O:
-0.45%
H:
5.15%
C:
0.3%
bbp-671
pharma
positive
phase 1
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published:
2022-05-20
(Crawled : 12:00)
- globenewswire.com
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
249.9%
|
O:
3.42%
H:
2.83%
C:
2.7%
ptr-01
treatment
pharma
trial
positive
therapy
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published:
2022-03-14
(Crawled : 12:30)
- biospace.com/
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
190.84%
|
O:
-1.04%
H:
0.0%
C:
0.0%
phase 2
muscular dystrophy
pos
positive
pharma
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.